Northern Trust Corp raised its stake in Hologic, Inc. (NASDAQ:HOLX) by 2.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,276,578 shares of the medical equipment provider’s stock after acquiring an additional 69,596 shares during the period. Northern Trust Corp’s holdings in Hologic were worth $158,587,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in HOLX. Horan Capital Advisors LLC. acquired a new stake in shares of Hologic during the first quarter worth about $33,000. First Interstate Bank acquired a new stake in shares of Hologic during the first quarter worth about $40,000. Lindbrook Capital LLC acquired a new stake in shares of Hologic during the fourth quarter worth about $36,000. Quadrant Capital Group LLC boosted its stake in shares of Hologic by 1,363.2% during the first quarter. Quadrant Capital Group LLC now owns 995 shares of the medical equipment provider’s stock worth $47,000 after buying an additional 927 shares during the period. Finally, Bronfman E.L. Rothschild L.P. boosted its stake in shares of Hologic by 90.1% during the fourth quarter. Bronfman E.L. Rothschild L.P. now owns 1,194 shares of the medical equipment provider’s stock worth $49,000 after buying an additional 566 shares during the period. Institutional investors own 96.41% of the company’s stock.
In other Hologic news, Director Sally Crawford sold 12,306 shares of the stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $47.61, for a total value of $585,888.66. Following the completion of the transaction, the director now directly owns 168,886 shares of the company’s stock, valued at $8,040,662.46. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Peter J. Valenti III sold 4,545 shares of the stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $44.07, for a total transaction of $200,298.15. The disclosure for this sale can be found here. Company insiders own 0.90% of the company’s stock.
NASDAQ HOLX traded up $0.31 during trading hours on Wednesday, hitting $48.07. 19,955 shares of the stock were exchanged, compared to its average volume of 1,751,947. Hologic, Inc. has a 12-month low of $37.47 and a 12-month high of $48.82. The company has a quick ratio of 1.02, a current ratio of 1.45 and a debt-to-equity ratio of 1.31. The stock has a market capitalization of $12.80 billion, a P/E ratio of 21.53, a P/E/G ratio of 2.17 and a beta of 0.69.
Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, May 1st. The medical equipment provider reported $0.58 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.57 by $0.01. Hologic had a negative net margin of 0.32% and a positive return on equity of 26.73%. The company had revenue of $818.40 million during the quarter, compared to analysts’ expectations of $806.99 million. During the same period last year, the company posted $0.53 earnings per share. The firm’s quarterly revenue was up 3.7% compared to the same quarter last year. On average, equities research analysts expect that Hologic, Inc. will post 2.42 earnings per share for the current fiscal year.
Several research firms recently issued reports on HOLX. ValuEngine cut shares of Hologic from a “buy” rating to a “hold” rating in a report on Tuesday, April 16th. Zacks Investment Research cut shares of Hologic from a “hold” rating to a “sell” rating in a report on Wednesday, April 10th. TheStreet cut shares of Hologic from a “b” rating to a “c+” rating in a report on Wednesday, May 1st. Finally, BidaskClub cut shares of Hologic from a “buy” rating to a “hold” rating in a report on Tuesday, April 16th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and seven have given a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $45.02.
COPYRIGHT VIOLATION WARNING: “Hologic, Inc. (NASDAQ:HOLX) Shares Bought by Northern Trust Corp” was published by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://transcriptdaily.com/2019/06/12/hologic-inc-nasdaqholx-shares-bought-by-northern-trust-corp.html.
Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.